Berdazimer sodium

Berdazimer sodium, sold under the brand name Zelsuvmi, is a medication used for the treatment for molluscum contagiosum. Berdazimer sodium is a nitric oxide releasing agent. It is a polymer formed from sodium 1-hydroxy-3-methyl-3-(3-(trimethoxysilyl)propyl)-1-triazene-2-oxide and tetraethyl silicate.

Berdazimer sodium was approved for medical use in the United States in January 2024.

Medical uses
Berdazimer sodium is indicated for the topical treatment of molluscum contagiosum.

Mechanism of action
Berdazimer sodium is a nitric oxide releasing agent. The mechanism of action for the treatment of molluscum contagiosum is unknown.

Pharmacodynamics
The pharmacodynamics of berdazimer sodium are unknown.

Legal status
Berdazimer sodium was approved for medical use in the United States in January 2024.

Names
Berdazimer sodium is the international nonproprietary name.